



CIN: L01400TG1986PLC062463

# ARUNJYOTI BIO VENTURES LTD.

To,

Date: 30.05.2022

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2022

Ref: Our Company's letter dated 18.05.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Arunjyoti Bio Ventures Limited held on Monday, 30.05.2022 at 4:00 p.m. at the registered office of the company the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2022. **(Enclosed)**
2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2022. **(Enclosed)**

The meeting concluded at **4:30 P.M**

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,  
For Arunjyoti Bio Ventures Limited

Pabbathi Praveen Kumar  
Whole-time Director & CFO  
(DIN: 02009879)

Encl: as above

| PART II - AUDITED STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2022 |  |                              |   |                                     |               |               |
|--|--|------------------------------|---|-------------------------------------|---------------|---------------|
| Name of the Company - <b>Arunjyoti Bio Ventures Limited</b>  |  |                              |   |                                     |               |               |
| Profit and Loss Statement for the Quarter and Year ended <b>31ST MARCH, 2022</b>                         |  |                              |   |                                     |               |               |
|  |  |                              |   | Amounts in Lakhs                    |               |               |
|  |  | Quarter Ended                |   |                                     | Year Ended    |               |
|  |  | 3 Months Ended<br>31/03/2022 | Preceeding 3 Months Ended<br>31/12/2021 | Corsp. 3 months ended<br>31/03/2021 | 3/31/2022     | 3/31/2021     |
|  |  | Audited                      | Unaudited                               | Audited                             | Audited       | Audited       |
| I  | Revenue from Operations  | -                            | -                                       | 219.60                              | 297.08        | 551.29        |
| II   | Other Income   | 27.99                        | -                                       | 0.15                                | 27.99         | 0.18          |
| III  | <b>Total Revenue (I+II)</b>  | <b>27.99</b>                 | <b>-</b>                                | <b>219.75</b>                       | <b>325.07</b> | <b>551.47</b> |
| IV   | <b>Expenses</b>  |                              |   |                                     |               |               |
|  | Cost of Material Consumed  | -                            | -                                       | -                                   | -             | -             |
|  | Purchase of Stock-in-trade   | 2.59                         | -                                       | 170.19                              | 287.46        | 466.35        |
|  | Changes in inventories of finished goods, Work in progress and Stock in trade  | (1.40)                       | -                                       | 2.03                                | -             | 0.37          |
|  | Employee benefits expense  | 2.92                         | 1.22                                    | 13.64                               | 6.36          | 23.79         |
|  | Finance Costs  | 0.03                         | 0.02                                    | 0.06                                | 0.09          | 0.16          |
|  | Direct Expenses  | -                            | -                                       | 14.69                               | 0.67          | 14.69         |
|  | Depreciation and Amortisation expense  | -                            | -                                       | -                                   | -             | -             |
|  | Other Expense  | 0.60                         | 0.91                                    | 23.16                               | 22.88         | 36.89         |
|  | <b>Total Expenses</b>  | <b>4.74</b>                  | <b>2.15</b>                             | <b>223.77</b>                       | <b>317.46</b> | <b>542.25</b> |
| V  | <b>Profit/(Loss) from before Prior Period Expenses and tax (I-IV)</b>  | <b>23.25</b>                 | <b>(2.15)</b>                           | <b>(4.02)</b>                       | <b>7.61</b>   | <b>9.22</b>   |
| VI   | Prior Period Expenses  | -                            | -                                       | -                                   | -             | -             |
| VII  | <b>Profit/(Loss) before tax (V-VI)</b>   | <b>23.25</b>                 | <b>(2.15)</b>                           | <b>(4.02)</b>                       | <b>7.61</b>   | <b>9.22</b>   |
| VIII   | <b>Tax Expense:</b>  |                              |   |                                     |               |               |
|  | Current Tax  | -                            | -                                       | 2.40                                | 1.98          | 2.40          |
|  | Deferred Tax   | -                            | -                                       | -                                   | -             | -             |
| IX   | Profit/ (Loss) for the period from Continuing operations (VII-VIII)  | 23.25                        | (2.15)                                  | (6.42)                              | 5.63          | 6.82          |
| X  | Profit/ (Loss) from discontinuing operations   | -                            | -                                       | -                                   | -             | -             |
| XI   | Tax Expense of discontinuing operations  | -                            | -                                       | -                                   | -             | -             |
| XII  | Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)   | -                            | -                                       | -                                   | -             | -             |
| XIII   | Profit/ (Loss) for the period (IX+XII)   | 23.25                        | (2.15)                                  | (6.42)                              | 5.63          | 6.82          |
| XIV  | Other Comprehensive Income<br>A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss<br>(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss | -                            | -                                       | -                                   | -             | -             |
| XV   | Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)  | 23.25                        | (2.15)                                  | (6.42)                              | 5.63          | 6.82          |
| XVI  | Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)<br>1) Basic<br>2) Diluted   | 1.12                         | (0.01)                                  | (0.31)                              | 0.27          | 0.33          |

|      |   |        |        |        |        |        |
|------|---|--------|--------|--------|--------|--------|
| XVII | Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)<br>1) Basic<br>2) Diluted              | -      | -      | -      | -      | -      |
| XVII | Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)<br>1) Basic<br>2) Diluted | 1.12   | (0.01) | (0.31) | 0.27   | 0.33   |
| XIX  | Paid Up Equity Share Capital (Face Value of INR 10/- per share)   | 207.09 | 207.09 | 207.09 | 207.09 | 207.09 |
| XX   | Reservers & Surplus (Excluding Revaluation Reserve)   |        |        |        |        |        |


**Notes:**


1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on 30th May, 2022.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
4. The figures of the current quarter ended 31st March, 2022 and the quarter ended 31st March, 2021 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
5. The results are also available on the website of the Company [www.orbisagri.com](http://www.orbisagri.com)
6. The Company is engaged in "Trading of Hardware and Agriculture Inputs" operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"

For ARUNJYOTI BIO VENTURES LIMITED

Place : Hyderabad  
Date : 30-05-2022

PABBATHI PRAVEEN KUMAR  
Wholetime Director  
(DIN: 02009879)

| <b>Arunjyoti Bio Ventures Limited</b><br><b>CIN NO: L01400TG1986PLC062463</b><br><b>Plot No. 45, P &amp; T Colony, Karkhana Secunderabad Hyderabad TG 500009 IN</b><br><b>Financial Position as at March 31, 2022</b>   |          |                    |                    |
|---|----------|--------------------|--------------------|
| Particulars   | Note No. | As at Mar 31, 2022 | As at Mar 31, 2021 |
| <b>I ASSETS</b>   |          |                    |                    |
| <b>1 Non-current assets</b>   |          |                    |                    |
| (a) Property, plant and equipment   | 3        | -                  | -                  |
| (b) Right to use assets   |          | -                  | -                  |
| (c) Capital work in progress  |          | -                  | -                  |
| (d) Investment properties   |          | -                  | -                  |
| (e) Good will   |          | -                  | -                  |
| (f) Other intangible Assets   |          | -                  | -                  |
| (g) Intangible Assets under Development   |          | -                  | -                  |
| (h) Biological Assets other than Bearer Plants  |          | -                  | -                  |
| (d) Financial assets  |          | -                  | -                  |
| (i) Investments   | 4        | -                  | -                  |
| (ii) Trade receivables  | 5        | -                  | -                  |
| (iii) Loans   | 6        | 1,04,627           | 1,49,71,192        |
| (e) Deferred Tax Asset (Net)  | 7        | -                  | -                  |
| (f) Other non-current asset   | 8        | 99,05,079          | -                  |
| <b>Total non-current assets (A)</b>   |          | <b>1,00,09,706</b> | <b>1,49,71,192</b> |
| <b>2 Current assets</b>   |          |                    |                    |
| (a) Inventories   | 9        | -                  | 2,59,478           |
| (a) Financial assets  |          |                    |                    |
| (i) Investments   | 4        | -                  | -                  |
| (ii) Trade receivables  | 5        | 53,91,456          | 1,83,81,369        |
| (iii) Cash and cash equivalents   | 10       | 73,613             | 80,87,045          |
| (iv) Bank Balances other than (iii) above   |          | -                  | -                  |
| (b) Current Tax Asset (Net)   | 7        | -                  | -                  |
| (c) Other current assets  | 11       | 54,75,539          | 53,33,981          |
| <b>Total current assets (B)</b>   |          | <b>1,09,40,608</b> | <b>3,20,61,873</b> |
| Non Current Assets Clasified as Held for Sale (C)   | 11.1     | -                  | -                  |
| <b>Total assets (A+B+C)</b>   |          | <b>2,09,50,314</b> | <b>4,70,33,065</b> |
| <b>II EQUITY AND LIABILITIES</b>  |          |                    |                    |
| <b>1 Equity</b>   |          |                    |                    |
| (a) Equity share capital  | 12       | 2,07,09,000        | 2,07,09,000        |
| (b) Other equity  | 12.1     | (6,95,910)         | (12,57,727)        |
| <b>Total equity (A)</b>   |          | <b>2,00,13,090</b> | <b>1,94,51,273</b> |
| <b>2 Liabilities</b>  |          |                    |                    |
| <b>(i) Non-current liabilities</b>  |          |                    |                    |
| (a) Financial Liabilities   |          |                    |                    |
| (i) Borrowings  | 13       | -                  | -                  |
| (ii) Trade Payables   | 14       | -                  | -                  |
| (iii) Other Financial Liabilities   | 15       | -                  | -                  |
| (b) Long term provisions  | 16       | -                  | -                  |
| (c) Deferred tax Liabilities(Net)   | 7        | -                  | -                  |
| (d) Other non Current Liabilities   |          | -                  | -                  |
| <b>Total non-current liabilities (B)</b>  |          | <b>-</b>           | <b>-</b>           |
| <b>(ii) Current liabilities</b>   |          |                    |                    |
| (a) Financial liabilities   |          |                    |                    |
| (i) Borrowings  | 13       | -                  | -                  |
| (ii) Trade payables   | 14       | 1,67,925           | 1,31,03,211        |
| (iii) Other financial liabilities   | 15       | -                  | -                  |
| (b) Short term provisions   | 16       | 2,39,838           | 2,39,838           |
| (c) Other current liabilities   | 17       | 5,29,461           | 1,42,38,743        |
| (d) Current Tax Laibilities (net)   | 7        | -                  | -                  |
| <b>Total current liabilities (C)</b>  |          | <b>9,37,224</b>    | <b>2,75,81,792</b> |
| <b>Total liabilities (D=B+C)</b>  |          | <b>9,37,224</b>    | <b>2,75,81,792</b> |
| <b>Total equity and liabilities (A+D)</b>   |          | <b>2,09,50,314</b> | <b>4,70,33,065</b> |
| <div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> Place : Hyderabad<br/> Date : 30-05-2022 </div> <div style="text-align: center;"> Arunjyoti Bio Ventures Limited<br/> <br/> Pabbathi Praveen Kumar<br/> Wholetime Director<br/> DIN:02009879 </div> </div> |          |                    |                    |

| <b>Arunjyoti Bio Ventures Limited</b><br><b>CIN NO: L01400TG1986PLC062463</b><br><b>Plot No. 45, P &amp; T Colony, Karkhana Secunderabad Hyderabad TG 500009 IN</b><br><b>CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2021</b>  |                               |                               |
|--|-------------------------------|-------------------------------|
|  | <b>As at Mar 31,<br/>2022</b> | <b>As at Mar 31,<br/>2021</b> |
| <b>A CASH FROM OPERATING ACTIVITIES</b>  |                               |                               |
| (Loss)/Profit before tax and extraordinary items   | 7,60,222                      | 9,22,451                      |
| <b>Adjustment for:</b>   |                               |                               |
| Income tax expense recognised in profit or loss  | -                             | -                             |
| Finance costs recognised in profit or loss   | -                             | -                             |
| Investment income recognised in profit or loss   | -                             | -                             |
| Gain on disposal of property, plant and equipment  | -                             | -                             |
| <b>Operating Profit before Working Capital Changes</b>   | <b>7,60,222</b>               | <b>9,22,451</b>               |
| <b>Movement for Working Capital:</b>   |                               |                               |
| Increase in trade and other receivables  | 1,29,89,913                   | 83,44,112                     |
| (Increase)/decrease in amounts due from customers under construction contracts   | -                             | -                             |
| (Increase)/decrease in inventories   | 2,59,478                      | 37,006                        |
| (Increase)/decrease in other assets  | (1,41,558)                    | 4,90,538                      |
| Decrease in trade and other payables   | (1,29,35,286)                 | (87,39,028)                   |
| Increase/(decrease) in amounts due to customers under construction contracts   | -                             | -                             |
| Increase/(decrease) in provisions  | -                             | (12,022)                      |
| (Decrease)/increase in deferred revenue  | -                             | -                             |
| (Decrease)/increase in other liabilities   | (1,37,10,030)                 | (38,95,260)                   |
| <b>Changes in non current assets and liabilities</b>   |                               |                               |
| Decrease/(Increase) in loans & advances  | 1,48,66,565                   | -                             |
| Decrease/(Increase) in Long Term Provisions  | -                             | -                             |
| Decrease/(Increase) in Other non Current Assets  | (99,05,079)                   | -                             |
| <b>Cash generated from operations</b>  | <b>(78,15,775)</b>            | <b>(28,52,203)</b>            |
| - Income taxes paid  | (1,97,657)                    | (2,64,463)                    |
| <b>Net Cash flow before extraordinary items</b>  | <b>(80,13,432)</b>            | <b>(31,16,666)</b>            |
| - Extraordinary & Prior period items   | -                             | -                             |
| <b>NET CASH FROM OPERATING ACTIVITIES</b>  | <b>(80,13,432)</b>            | <b>(31,16,666)</b>            |
| <b>B CASH FLOW FROM INVESTING ACTIVITIES:</b>  |                               |                               |
| Payments to acquire financial assets   | -                             | -                             |
| Proceeds on sale of financial assets   | -                             | -                             |
| Interest received  | -                             | -                             |
| Royalties and other investment income received   | -                             | -                             |
| <b>NET CASH FROM INVESTING ACTIVITIES</b>  | <b>-</b>                      | <b>-</b>                      |
| <b>C CASH FLOW FROM FINANCING ACTIVITIES</b>   |                               |                               |
| Proceeds from issue of equity instruments of the Company   | -                             | -                             |
| Proceeds from issue of convertible notes   | -                             | -                             |
| Payment for share issue costs  | -                             | -                             |
| Payment for buy-back of shares   | -                             | -                             |
| Payment for share buy-back costs   | -                             | -                             |
| <b>NET CASH FROM FINANCING ACTIVITIES</b>  | <b>-</b>                      | <b>-</b>                      |
| <b>NET INCREASE IN CASH &amp; CASH EQUIVALENTS</b>   | <b>(80,13,432)</b>            | <b>(31,16,666)</b>            |
| <b>Cash and cash equivalents at the beginning of the year 1.04.2021</b>  | <b>80,87,045</b>              | <b>1,11,76,399</b>            |
| Effects of exchange rate changes on the balance of cash held in foreign currencies   | -                             | -                             |
| <b>Cash and cash equivalents at the end of the year as on 31.03.2022</b>   | <b>73,613</b>                 | <b>80,59,733</b>              |
| <b>Reconciliation of cash and cash equivalents as per the cash flow Statement</b>  |                               |                               |
| Cash and cash equivalents (Note-10.1)  | 73,613                        | 80,87,045                     |
| Bank overdraft   | -                             | -                             |
| <b>Balance as per statement of cash flows</b>  | <b>73,613</b>                 | <b>80,87,045</b>              |
| <div style="text-align: center;">Arunjyoti Bio Ventures Limited</div> <div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div>           Place : Hyderabad<br/>           Date : 30-05-2022         </div> <div style="text-align: center;"> <br/>           Pabbathi Praveen Kumar<br/>           Wholtime Director<br/>           DIN:02009879         </div> </div> |                               |                               |



CIN: L01400TG1986PLC062463

## ARUNJYOTI BIO VENTURES LTD.

To,  
BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Date: 30.05.2022

Dear Sir,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, Pabbathi Praveen Kumar Whole time Director & CFO of Arunjyoti Bio Ventures Limited hereby declare that the statutory Auditors of the company, M/s. V. Ravi & Co, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2022.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely,

For Arunjyoti Bio Ventures Limited

Pabbathi Praveen Kumar  
Whole-time Director & CFO  
(DIN: 02009879)



**INDEPENDENT AUDITORS' REPORT****TO THE BOARD OF DIRECTORS OF Arun Jyothi Bio Ventures Limited,****Report on the audit of the Standalone Annual Financial Results****Opinion**

We have audited the accompanying standalone annual financial results of Arun Jyothi Bio Ventures Limited (hereinafter referred to as the "Company") for the year ended 31 March 2022 ('standalone annual financial results'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the company for the year ended March 31, 2022.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Board of Directors' Responsibilities for the Standalone Annual Financial Results**

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the


**Branches :****Head Office :**

Gr Floor, 2-6-1071,  
Road No. 2, KLN Reddy Colony  
Hanamkonda, Warangal Urban Dist  
Telangana - 506 001  
Mobile : 96521 08456  
vraviandco.ca@gmail.com

**Hyderabad :**  
H.No. 1-74/DH/301,  
Diamond Hills, Gachibowli  
Hyderabad.  
Telangana - 500 032  
Mobile : 90321 22231  
rajenderrao@gmail.com

**Karimnagar :**  
10-3-239,  
Vidyanagar  
Karimnagar  
Telangana - 505 001  
Mobile : 99893 13399  
rkdannapuneni@gmail.com

**Hanamkonda :**  
1-7-900/A/61,  
Nandi Hills, Hunter Road  
Hanamkonda, Warangal Urban Dist  
Telangana - 506 001  
Mobile : 99894 15638  
wglauditors@gmail.com





Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors is responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If





we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters:**

The statement includes the results for the quarter ended March 31, 2022 being the balance figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

For **V RAVI & CO.,**  
Chartered Accountants  
Firm Reg No.006492S



Date: 30/05/2022  
Place: Hyderabad

**D Ramesh Kumar**  
Partner

Membership No.217139  
UDIN: 22217139AJWDHY8894